Monoamine oxidase inhibition improves vascular function in mammary arteries from nondiabetic and diabetic patients with coronary heart disease

Citations Over TimeTop 12% of 2016 papers

Abstract

Monoamine oxidases (MAOs) are mitochondrial enzymes with 2 isoforms that have emerged as important contributors to cardiovascular oxidative stress via the constant generation of hydrogen peroxide. The present study was purported to assess whether MAO-derived H₂O₂ contributes to the endothelial dysfunction in mammary arteries harvested from coronary heart disease patients with and without diabetes mellitus subjected to coronary artery bypass grafting. To this aim, the effects of MAO inhibition on vascular contractility to phenylephrine and endothelial-dependent relaxation (EDR) in response to acetylcholine were studied in vascular segments. Clorgyline (irreversible MAO-A inhibitor), selegiline (irreversible MAO-B inhibitor), and moclobemide (reversible MAO-A inhibitor) were applied in the organ bath (10 μmol/L). MAO expression was assessed by immunohistochemistry. We found a constant impairment of EDR that has been significantly attenuated in the presence of the MAO-A and MAO-B inhibitors in both groups of coronary heart disease patients. MAO-B was the dominant isoform in all human diseased vessels. In conclusion, in vitro inhibition of MAO significantly improved EDR in human mammary arteries, regardless of the presence of diabetes. These data suggest that MAO inhibitors might be useful in restoring endothelial response in clinical conditions associated with increased oxidative stress, such as coronary artery disease and diabetes.

Related Papers

• → Clinical Applications of MAO-Inhibitors(2004)224 cited
• → Pharmacokinetic-Pharmacodynamic Interactions Between Two Selective Monoamine Oxidase Inhibitors: Moclobemide and Selegiline(1996)20 cited
• → Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline(1996)16 cited
• Reversal of stress-induced deficit in aggression by monoamine oxidase inhibitors.(2000)
• → The evolving role of monoamine oxidase inhibitors in the treatment of Parkinson’s disease(2004)1 cited